Literature DB >> 9384469

Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes.

X J Zhao1, T Ishizaki.   

Abstract

AIMS: Nine antimalarial (plus two metabolites of proguanil) and twelve non-antimalarial drugs were tested for their possible interaction with CYP3A4-catalysed 3-hydroxylation of quinine by human liver microsomes in vitro.
METHODS: 3-Hydroxyquinine was assayed in the incubation mixture by an h.p.l.c. method using fluorometric detection. The respective IC50 values were estimated for the twenty-one drugs and two metabolites of proguanil tested herein.
RESULTS: Thirteen drugs exhibited an inhibitory effect on the 3-hydroxylation of quinine. According to the respective mean IC50 values, the inhibitory rank order of the drugs was: ketoconazole > troleandomycin (TAO, with preincubation) > doxycycline > omeprazole > primaquine > tetracycline = TAO (without preincubation) > nifedipine > erythromycin > verapamil > cimetidine > diltiazem > oleandomycin > hydralazine. Other drugs or metabolites showed little or no inhibition of quinine metabolism (mean IC50 > 200 or 500 microM). Among the antimalarial drugs, doxycycline showed relatively potent inhibition of quinine 3-hydroxylation with a mean IC50 value of 17 microM, followed by primaquine and tetracycline, with mean IC50 values of 20 and 29 microM, respectively.
CONCLUSIONS: When the plasma/serum concentrations possibly attained after their usual therapeutic doses were taken into account, tetracycline, doxycycline, omeprazole, ketoconazole, nifedipine, TAO and erythromycin are likely to be inhibitors of quinine metabolism in patients when the drugs are co-administrated with quinine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9384469      PMCID: PMC2042867          DOI: 10.1046/j.1365-2125.1997.t01-1-00619.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Synergistic in vitro antimalarial activity of omeprazole and quinine.

Authors:  T Skinner-Adams; T M Davis
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers.

Authors:  Peter U Bassi; Cyprian O Onyeji; Otas E Ukponmwan
Journal:  Br J Clin Pharmacol       Date:  2004-07       Impact factor: 4.335

3.  Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man.

Authors:  Rajaa A Mirghani; Orjan Ericsson; Gunnel Tybring; Lars L Gustafsson; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2003-03-11       Impact factor: 2.953

Review 4.  The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.

Authors:  Brooke M VandenBrink; Nina Isoherranen
Journal:  Curr Opin Drug Discov Devel       Date:  2010-01

Review 5.  Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters.

Authors:  Slobodan Rendic; Frederick Peter Guengerich
Journal:  Curr Drug Metab       Date:  2020       Impact factor: 3.731

6.  A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition.

Authors:  X J Zhao; T Ishizaki
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jul-Sep       Impact factor: 2.569

7.  Effect of ketoconazole, a cytochrome P450 inhibitor, on the efficacy of quinine and halofantrine against Schistosoma mansoni in mice.

Authors:  Sayed Hassan Seif El-Din; Abdel-Nasser Abdel-Aal Sabra; Olfat Ali Hammam; Naglaa Mohamed El-Lakkany
Journal:  Korean J Parasitol       Date:  2013-04-25       Impact factor: 1.341

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.